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SUMMARY
Some patients under antiretroviral therapy (ART) do not reach immune recovery when the viral load becomes undetectable. 
This is called discordant immunologic and virologic responses. Its prevalence varies between 8% and 24%. This study describes its 
prevalence and the characteristics of the affected subjects in the outpatient clinic of a Brazilian specialized-care center. Of 934 patients 
on ART, 536 had undetectable viral loads. Prevalence was 51/536 or 9% (95% confidence interval: 6.6% to 11.4%). Median age at the 
beginning of ART was 37 years (interquartile range - IQR: 31 to 45). Male gender and mixed race predominated (76.5% and 47.1% 
respectively). AIDS-defining illnesses were absent at the beginning of ART in 60.8%. Fifty-one percent were taking protease inhibitors, 
43.2% Efavirenz and 5.8% both. Median time on ART was 36 months (IQR: 17-81 months). Irregular treatment was recorded for 
21.6%. ART had been modified for 63% prior to the study, and 15.7% had used monotherapy or double therapy. Median CD4 count 
was 255 cells/mm3 (IQR: 200-284). Median viral load before ART was 4.7 log10 copies/mL (IQR: 4.5-5.2). Discordant responders 
were not different from AIDS patients in general, but there was a high frequency of multiple schedules of treatment.
KEYWORDS: Acquired immunodeficiency syndrome; CD4 lymphocyte count; Highly active antiretroviral therapy; Discordant 
immunologic and virologic responses.
INTRODUCTION
With the advent of Highly Active Antiretroviral Therapy (HAART), 
which became available in Brazil in 1996, Acquired Immune Deficiency 
Syndrome (AIDS) has become a chronic condition. This change is a 
consequence of the reduction in both the morbidity and mortality of AIDS, 
with an additional gain in the quality of life of affected individuals21,40.
Current antiretroviral therapy (ART) is highly efficacious in reducing 
the viral load of the Human Immunodeficiency Virus (HIV) to undetectable 
levels and providing a consistent increase in the number of CD4+ T 
lymphocytes21,39. The resulting effect is the desired recovery of the 
immune system, known as immune reconstitution. However, it has been 
very difficult to define an ideal immune response and there is no precise 
definition of what an immune reconstitution could be. A number of studies 
in the literature have used different criteria, namely, either using CD4 cell 
count (for which “normal” values or a minimum increase are determined) 
or the time on ART required to allow immune reconstitution (Box 1).
Even taking into account the fact that the definitions of therapeutic 
response and therapeutic failure vary, the prevalence of discordant 
immunologic and virologic responses in patients on ART varies between 
8% and 42% (Box 1).
As the frequency of discordant immunologic and virologic responses 
in patients on ART varies greatly in care centers around the world, it is 
important to determine the prevalence of this response in Brazilian HIV/
AIDS outpatient departments as a first step to better understanding the 
consequences of this condition for the treatment as a whole. This was 
the aim of the present study.
MATERIALS AND METHODS
Study location: The infectious-diseases outpatient clinic of the 
Cassiano Antonio de Moraes University Hospital (HUCAM) is located 
in the city of Vitória, Espírito Santo (ES), Brazil. It is a local reference 
center for patients living with HIV/AIDS. In April 2009, the clinic was 
responsible for the care of about 30% of the 2,700 patients under ART 
in the state (data provided by the STD/AIDS Coordination Section of 
the State Department of Health - SESA).
The clinic has a staff of eleven infectious-diseases specialists, two 
nurses, one social worker, three nurse assistants and one pharmacist. 
Every patient has a reference physician who is responsible for the 
patient’s care at each visit.
Study population: The study population consisted of the 934 AIDS 
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patients on ART registered at HUCAM and attended to at the outpatient 
clinic from April to September 2009.
Study design: The study is a cross-sectional analysis in which data 
was obtained by reviewing the records of patients registered at the clinic 
over the six-month period from April 1st 2009 to September 30th 2009. 
The prevalence of discordant immunologic and virologic responses was 
calculated by dividing the number of patients meeting the eligibility 
criteria for paradoxical response (numerator) by the number of patients 
on ART for more than a year with suppressed viral load (denominator). 
The review of patient records also allowed the profile of patients with 
discordant immunologic and virologic responses to be determined in 
terms of sociodemographic, clinical and laboratory variables.
Definitions: Discordant immunologic and virologic responses were 
defined for the purpose of this study as the response observed in patients 
with suppressed viral load but CD4 cell counts below 350 cells/mm3,8. 
This cut-off limit was based on studies showing lower frequencies of 
AIDS-defining illnesses and death among patients on ART with CD4 
cell counts greater than or equal to 350 cells/mm3,6.
Viral suppression or undetectable viral load was defined as a count 
of less than 50 copies/mL, the limit most frequently used as a reference 
since molecular-biological techniques for determining viral load became 
available in Brazil.
HIV infection was defined in accordance with criteria adopted by 
the Ministry of Health in Brazil.
Inclusion criteria: Inclusion criteria were: age equal to or greater 
than 18 years; being registered in the HUCAM outpatient clinic; having 
been using ART for more than 12 months on the date of inclusion; 
CD4 cell counts persistently below 350 cells/mm3 over the previous six 
months, as determined by two separate measurements; and HIV viral 
load undetectable over the previous six months.
Exclusion criteria: Exclusion criteria were: (i) having taken part 
in the ART discontinuation program at any time during follow-up at 
the outpatient clinic; (ii) having undergone treatment with interferon or 
chemotherapy during the preceding year; (iii) being considered to have 
had immunological failure during the preceding year (a decline greater 
than 25% in the CD4 cell count); (iv) being considered to have had clinical 
failure (relapse of a defining illness after three or more months of ART); 
(v) irregular use of ART over the previous year, defined as interruption 
of drug use for more than 30 consecutive days at any time; (vi) failure 
to attend the clinic in the previous six months; (vii) being pregnant at 
the time of the sampling.
Ethical considerations: The study was approved by the local 
Research Ethics Committee on September 30th 2009, under registration 
number 087/09.
RESULTS
Of the 934 patients taking ART from April to September 2009, 563 
had undetectable viral loads (less than 50 copies/mL) in the six months 
preceding the beginning of data collection (October 10th 2009). Among 
those with undetectable viral loads, 107 had CD4 cell counts below 
350 cells/mm3. Of these 107 patients, 29 had taken ART for less than a 
year, 19 had only one CD4 cell count below 350 cells/mm3, three were 
followed up through home assistance and did not attend the outpatient 
clinic, two were absent from the clinic during the preceding six months, 
two had received interferon and one had failed to take ART for more 
than 30 days. Thus, 51 patients were considered to definitely be having a 
BOX 1
Synthesis of studies of the prevalence of discordant immunologic and virologic responses and the definitions of immune response used
Author
Definition of Immune Response Frequency 
of discordant 
responses
ReferenceNumber of CD4 cells necessary for 
a definition of immune response
Period on ART used to evaluate the 
presence of immune response
RENAUD et al. 1999 Increase of 50 2 months 8% 32
MOORE et al. 2005 Increase of 50 3 to 9 months 15.4% 24
TAN et al. 2008 Increase of 50 3 to 9 months 8.7% 37
PIKETTY et al. 1998 Increase of 50 5.5 months (median) 10.5% 29
GRABAR et al. 2000 Increase of 50 6 months 17.3% 12
TUBOI et al. 2007 Increase of 50 6 months 19% 41
GUTIERREZ et al. 2008 Increase of 50 6 months 16.6% 14
FLORENCE et al. 2003 Increase of 50 to 75 7 to 12 months 29% 9
BARREIRO et al. 1999 Increase of 60 6 months 26.9% 1
GILSON et al. 2010 Increase of 100 6 to 10 months (median: 8 months)
10 to 14 months (median: 12 months)
32.1%
24.2%
10
PIKETTY et al. 2001 Increase of 100 12 months 9% 30
NICASTRI et al. 2005 Increase of 100 12 months 15.7% 28
FALSTER et al. 2009 ≥ 350 9 to 24 months 28% 8
KELLEY et al. 2009 CD4 > 500 4 years 41% 17
CD4: CD4+ T-lymphocyte count; ART: antiretroviral therapy.
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paradoxical response. Hence, for a total of 563 patients undergoing ART 
with undetectable viral loads, the prevalence of those with discordant 
immunologic and virologic responses in this specialized center was 9%, 
with a 95% confidence interval (CI 95%) from 6.6% to 11.4% (Fig. 1).
Demographic and epidemiologic characteristics are presented in 
Table 1, and clinical data and characteristics of the disease process in 
Tables 2 and 3. Males (39; 76.5%) and mixed race/colored individuals 
(24; 47.1%) predominated in the study population (Table 1). Thirty-one 
patients (60.8%) did not have any defining illnesses before they started 
ART (Table 2). Median age at the beginning of ART was 37 years, with 
an interquartile range (IQR) of 31 to 45 (Table 3).
Twenty-six patients (51%) were taking protease inhibitors (PIs) 
with or without Ritonavir as a booster, while twenty-two (43.2%) were 
taking Efavirenz and three patients (5.8%) were taking both classes of 
agents. The median total time under therapy since the first regimen was 
36 months (IQR 17-81). Irregular treatment was recorded for 21.6%. ART 
had been modified for 63% prior to the study, and 15.7% had undergone 
monotherapy or double therapy (Table 2).
Median time during which there was an undetectable viral load was 
12 months (IQR: 6 - 24) and the corresponding figure for a viral load 
below 1,000 copies/mL was 14 months (IQR: 8 - 46). Median viral 
load (log10 copies/mL) before the first ART regimen was 4.7 (4.2 - 5.2) 
and median nadir CD4 cell count was 56 cells/mm3 (IQR: 20 - 108). 
Median CD4 cell count before the beginning of the first ART regimen 
was 75 cells/mm3 (IQR: 24 - 185). Current median CD4 cell count (i.e., 
cell count in the last six months of follow-up) was 255 cells/mm3 (IQR: 
200 - 284) (Table 3).
Fig. 1 - Flowchart illustrating the procedure used to select cases of discordant immunologic 
and virologic responses in order to calculate prevalence.
Table 1 
Descriptive demographic and epidemiologic characteristics of the 51 
individuals with discordant immunologic and virologic responses 
Characteristics Absolute 
Number
Percentage
Gender
     Female
     Male
12
39
23.5
76.5
Race/color
     White
     Mixed
     Black
     Yellow
     Unknown
16
24
8
1
2
31.4
47.1
15.7
2
3.9
Possible sexual transmission of HIV
     Yes
     No
     Unknown
49
1
1
96.1
2
2
Possible transmission by intravenous 
drug use
     Yes
     No
     Unknown
6
44
1
11.8
86.3
2
DISCUSSION
The prevalence of discordant immunologic and virologic responses in 
the present study was 9%, a value which, despite the different definitions 
of this phenomenon, is within the range of values reported by others 
(between 8% and 16%)14,24,28-30,32,37. 
Higher prevalence has been reported by other authors. These vary 
between 17% and 21%12,41 and above 24%1,8-10,17. The discrepancies 
can be explained by the different criteria used to define the discordant 
response, especially as far as CD4 cell count is concerned. The period 
used to establish discordant immunologic and virologic responses also 
varied between studies1,8-10,12,14,17,24,28-30,32,37 (see Box 1).
In this study, 9.69% of the patients were forty years old or older. 
The median age of 37 years (IQR: 31 - 45) is similar to that observed in 
other studies9,10,12,14,24,28,41, as is the predominance of males8,9,10,12,14,24,27,37. 
Without suitable data for comparison, however, the importance of these 
characteristics is difficult to determine. Furthermore, such an analysis 
is not the purpose of this descriptive report. 
There was a predominance of mixed-race/colored patients (47.1%) 
followed by whites (31.4%) and blacks (15.7%). These findings differ 
from those of other authors who reported a predominance of white 
individuals9,10, but this represented the general characteristics of the 
patients attending the present outpatient clinic. The difference can be 
justified by the high degree of miscegenation of the Brazilian population.
The low median CD4 cell counts prior to the beginning of the 
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Table 2
Clinical characteristics of 51 individuals with discordant immunologic and 
virologic responses 
Characteristics Absolute 
Number
Percentage
AIDS-defining illness before the begin-
ning of ART
     Yes
     No
20
31
39.2
60.8
Definition of AIDS by the CDC criteria
     Yes
     No
18
33
35.3
64.7
Definition of AIDS by CD4 cell count 
below 350 cells/mm3
     Yes
     No
26
25
51
49
CDC criterion used for AIDS diagnosis 
(total: 18)
     Cerebral Toxoplasmosis
     Pneumocystis jiroveci Pneumonia
     Esophageal Candidiasis
     Cytomegalovirus infection
     Extrapulmonary Cryptococcosis
     Invasive Cervical Cancer
     Chronic Intestinal Isosporiasis
Report of irregular use of ART in the 
preceding year
     Yes
     No
Current ART regimen
     Containing a Protease Inhibitor with 
     Ritonavir (PI/r)
     Containing Efavirenz (EFZ)
     Containing PI/r and EFZ
Monotherapy or double therapy before 
HAART
     Yes
     No
6
3
3
2
2
1
1
11
40
26
22
3
8
43
33.3
16.7
16.7
11.1
11.1
5.5
5.5
21.6
78.4
51
43.2
5.8
15.7
84.3
ART: Antiretroviral therapy; CDC: Centers for Disease Control and Prevention, 
Atlanta; CD4: CD4+ T-lymphocyte count.
first ART regimen observed in the present study contrast with higher 
median values found in some studies (150 to 250 cells/mm3)9,10,12,24,28 
but are consistent with those reported by other authors8,37. The same 
observation is applicable to the nadir CD4 cell counts. Our finding of a 
median of 56 cells/mm3 (IQR: 20 - 108) contrasts with a median of 100 
cells/mm3 or above reported by others8,9. There is a clear possibility that 
discordant immunologic and virologic responses can be explained by 
severe immunodeficiency, as the immune system can be so depleted of 
CD4 cells that they cannot be replenished to their normal levels. Despite 
the apparent lower immunity of the subjects sampled in this report, the 
overall lower medians (below 200 cells/mm3) reported by several authors 
underline the relationship between the level of immunity preceding 
treatment and the ability to reconstitute the immune system.
A predominance of a given therapeutic regimen in subjects with 
discordant immunologic and virologic responses was not consistently 
observed either in this study or in those published by other authors. 
Several studies of discordant immunologic and virologic responses 
reveal variations in the regimens used like a marked predominance of 
PIs (87%)10,37,41 or a predominance of NNRTI (78%)8. A relatively high 
frequency of irregular treatment and regimen modification calls attention 
to adhesion as a determinant.
Discordant immunologic and virologic responses are surrounded by 
many uncertainties, some of them related to the absence of a uniform 
definition of ideal immune response and to the limitations imposed by 
the CD4 count as the only marker of immune reconstitution available 
in the daily practice. There are numerous different conclusions about 
the relevance of possible risk factors, such as advanced age at the 
beginning of ART9,11,13,15,18,19,24,28,30,41, low initial values of CD4 cell 
count8,9,17,18,22,25,34,35, high initial values of CD4 cell count2,7,9,10,24,28,36,41, low 
nadir CD4 cell count9, ART regimen24,42, different levels of initial viral 
load10,14,18,19,24,28,30,34,41, the presence of associated conditions12,34 and even 
category of exposure to HIV14,19,28.
Another controversial aspect of discordant immunologic and 
virologic responses is the outcome of these patients compared with 
those with complete immune reconstitution. Some studies found higher 
odds for defining illnesses and death among patients with discordant 
immunologic and virologic responses12,29,37, while others did not find 
differences in the outcomes16,26.
The mechanisms involved in the failure of immune reconstitution 
have not been completely clarified. While some researchers have 
hypothesized that it could be the consequence of impaired thymic 
function33,38, others considered the possibility of an association with 
genetic factors31. SACHDEVA et al.34 reported a limited capacity 
for a-interferon production in patients with PIR. Down-regulation 
of interleukin-7 (IL-7) has also been associated with discordant 
immunologic and virologic responses3-5, and an increase in absolute 
CD4 cell count was observed in patients experimentally treated with 
IL-7 in a phase I/IIa study20.
In conclusion, further studies are needed to clarify how the various 
putative factors interact to determine discordant immunologic and 
virologic responses. Studies of this subject should take into account not 
only the sociodemographic, clinical and laboratory factors, but also the 
qualitative and quantitative aspects of immunological variables.
Efforts are also required to standardize terms and definitions 
regarding discordant immunologic and virologic responses, as this would 
allow the results of the numerous studies on the subject in the international 
literature to be compared more effectively.
However, the first step in understanding discordant immunologic 
and virologic responses and its impact on the outcome and treatment 
of AIDS is to determine its frequency in different parts of the world, 
an objective to which this report has sought to contribute. Descriptive 
studies such as this can pave the way for analytical comparisons that 
will allow intervention strategies to be proposed to minimize the 
occurrence of this undesired response in the treatment of individuals 
with AIDS.
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RESUMO
Prevalência da resposta imunológica e virológica discordante 
em pacientes com AIDS sob terapêutica antirretroviral em 
ambulatório de centro de cuidados especializados no Brasil
Alguns pacientes sob terapêutica antirretroviral (TARV) não 
obtêm recuperação imune quando a carga viral se torna indetectável. 
Isto é chamado resposta imunológica e virológica discordante. A 
prevalência varia entre 8% e 24%. Este estudo descreve sua prevalência 
e características dos afetados em ambulatório de um centro de cuidados 
especializados brasileiro. De 934 pacientes sob TARV, 536 tinham 
carga viral indetectável. A prevalência foi 51/536, ou 9% (Intervalo de 
Confiança de 95% de 6,6% a 11,4%). Idade mediana no início da TARV 
foi 37 anos (distância interquartílica - DQ: 31 a 45). Gênero masculino 
e cor parda predominaram (76,5% e 47,1%, respectivamente). Doenças 
definidoras de Aids estavam ausentes no início da TARV em 60,8%. 
Cinquenta e um por cento recebiam inibidores da Protease, 43,2% 
Efavirenz e 5,8% ambos. Tempo mediano de TARV foi 36 meses (DQ: 
17-81). Tratamento irregular foi registrado em 21,6%. TARV havia sido 
anteriormente modificado em 63% e 15,7% haviam usado mono ou dupla 
terapêutica. A contagem mediana de CD4 foi 255 células/mm3 (DQ: 
200-284). O logaritmo mediano da carga viral antes do TARV foi 4,7 
(DQ: 4,5-5,2). Aqueles com resposta discordante não eram diferentes dos 
pacientes com AIDS em geral, mas houve alta frequência de múltiplos 
esquemas terapêuticos.
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